Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAGE-A4-specific TCR T cell therapy in solid tumors (TBI-1201)
jRCT2080222504Phase 1Completed
- Sponsor
- Mie University, Aichi Medical University, National Cancer Center Hospital, National Cancer Center Hospital East, Nagoya Medical Center, Keio University
- Start
- May 2014
- Modality
- Cell Therapies, Gene Therapies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TBI-1201 in Nonhematologic neoplasms (2 cohorts), sponsored by Mie University, Aichi Medical University, National Cancer Center Hospital, National Cancer Center Hospital East, Nagoya Medical Center, Keio University. Started May 2014; status: completed.
02
Drugs
TBI-1201
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080222504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222504.